Not available
Quote | Astellas Pharma Inc (OTCMKTS:ALPMF)
Last: | $9.521 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $9.521 |
High: | $0 |
Low: | $0 |
Volume: | 60 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Astellas Pharma Inc (OTCMKTS:ALPMF)
2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...
2024-05-01 13:54:38 ET Poseida Therapeutics ( NASDAQ: PSTX ) shares traded higher on Wednesday after the company and Japanese drugmaker Astellas ( OTCPK:ALPMY ) announced a partnership to develop and commercialize CAR-T cell therapies for cancer.... Read the full article o...
Message Board Posts | Astellas Pharma Inc (OTCMKTS:ALPMF)
Subject | By | Source | When |
---|---|---|---|
Astellas' Main Products: | scoobey-do | investorshub | 01/02/2021 7:43:55 PM |
Astellas Aspiration: | scoobey-do | investorshub | 01/02/2021 7:37:09 PM |
Astellas Innovation Management ($AIM) sounds like a partnership | SPORT19 | investorshub | 01/02/2021 5:25:04 PM |
One week ago ProtoKinetix $CEO Clarence Smith posted | SPORT19 | investorshub | 01/02/2021 5:24:42 PM |
Astellas has undergone a MASSIVE expansion of its | SPORT19 | investorshub | 01/02/2021 5:24:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...